GLP-3 RT vs GLP-2 T: Triple Agonist vs Dual Agonist
GLP-3 RT adds glucagon receptor agonism to the GLP-1/GIP profile of GLP-2 T. The Phase-2 data shows what that third receptor actually changes.
GLP-3 RT and GLP-2 T are both Eli Lilly incretin-mimetic peptides. GLP-2 T is a dual GLP-1/GIP receptor agonist. GLP-3 RT adds a third receptor — glucagon — to that profile.
On paper that third receptor sounds counterintuitive (glucagon raises glucose). In the published Phase-2 literature it is the receptor most associated with the larger reported effect size.
What the glucagon receptor adds
GLP-2 T acts on GLP-1 (satiety, insulin) and GIP (adipocyte and CNS modulation). GLP-3 RT adds glucagon receptor agonism, which intuitively seems wrong — glucagon raises blood sugar.
Mechanistically, glucagon receptor activation is associated in the literature with increased energy expenditure and hepatic lipid oxidation. Combined with GLP-1 and GIP receptor activity, the published Phase-2 data reported a larger effect size than the dual agonist.
Phase-2 data vs Phase-3 data
The published GLP-3 RT Phase-2 trial (n=338, 48 weeks, physician-supervised drug product) reported roughly 24% on its primary endpoint at the 12 mg arm — the largest figure published for any incretin peptide to date. Cited as literature context only.
GLP-2 T's SURMOUNT-1 (Phase-3, n=2,539, 72 weeks) reported ~20–22% at 15 mg. The comparison is not apples-to-apples — GLP-3 RT has not yet completed Phase-3 — but the trajectory is notable.
What's still unknown about GLP-3 RT
Long-term cardiovascular outcomes, hepatic safety signals at scale, and dose-response in larger populations are all still being characterized in ongoing Phase-3 trials (TRIUMPH program). GLP-2 T already has multi-year post-approval safety data.
Research verdict
GLP-3 RT has the larger reported effect sizes in early data, attributed to the addition of glucagon receptor agonism. GLP-2 T has the complete Phase-3 evidence base and regulatory approval. Researchers studying triple-receptor incretin pharmacology choose GLP-3 RT; researchers requiring fully-validated dual-agonist data choose GLP-2 T.
Literature notice
Any clinical trial figures referenced on this page describe published studies of approved, physician-supervised pharmaceutical drug products. They are cited for scientific literature context only. They are not results, claims, or representations about the research materials sold by Redline Bio Labs. All materials sold are supplied strictly for in-vitro laboratory research use only, are not drugs, and are not for human or veterinary consumption or administration of any kind.
Frequently asked questions
Is GLP-3 RT stronger than GLP-2 T?
In published Phase-2 literature, the GLP-3 RT 12 mg arm reported ~24% on its primary endpoint at 48 weeks vs ~20–22% for GLP-2 T 15 mg in SURMOUNT-1 at 72 weeks. Phase-3 head-to-head data is not yet published. These are clinical trial findings for drug products, not claims about research materials sold here.
Why does the glucagon receptor matter in this literature?
In the published literature, glucagon receptor activation is associated with increased energy expenditure and hepatic lipid oxidation. Combined with GLP-1 receptor activity, the reported net effect in trial data is a larger effect size despite glucagon's classical glucose-raising role.
Is GLP-3 RT approved?
No. It is investigational. The TRIUMPH Phase-3 program is ongoing. GLP-2 T is FDA-approved as Mounjaro (T2D) and Zepbound (weight management).